Heron Therapeutics appoints two new independent directors to board

HERON THERAPEUTICS, INC. /DE/

Sharmila Dissanaike, M.D. appointed to board effective Sept 20, 2021; she is a trauma surgeon and University Distinguished Professor at Texas Tech.
Susan Rodriguez appointed to board effective same date; she is Chief Commercial Officer of Ardelyx and has 25+ years biopharma experience.
Both directors will serve initial term until 2022 Annual Meeting; initial equity awards: 37,500 options and 6,250 RSUs each.
Both qualify as independent under Nasdaq rules; not immediately assigned to any Board committees.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Susan Rodriguez

Director

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2021-09-20
Filed: September 24, 2021, 7:59 PM ET

Effective as of September 20, 2021, the Board appointed Susan Rodriguez to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.

Appointed

Sharmila Dissanaike

Director

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2021-09-20
Filed: September 24, 2021, 7:59 PM ET

Effective as of September 20, 2021, the Board of Directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”) appointed Sharmila Dissanaike, M.D. to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Rodriguez was appointed as Director at HERON THERAPEUTICS, INC. /DE/.

Action: appointed
Role: Director

Exact text from the filing

Effective as of September 20, 2021, the Board appointed Susan Rodriguez to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sharmila Dissanaike was appointed as Director at HERON THERAPEUTICS, INC. /DE/.

Action: appointed
Role: Director

Exact text from the filing

Effective as of September 20, 2021, the Board of Directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”) appointed Sharmila Dissanaike, M.D. to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0001564590-21-048772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.